Psoriasis Therapeutics in Asia-Pacific Markets to 2021

1. Top 10 Diabetes Care Technologies, Devices and Therapeutics Markets - Growth, Global Share, Industry Overview, Analysis, Trends Opportunities and Forecast 2012 - 2020 Psoriasis Therapeutics in Asia-Pacific Markets to 2021: Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth

2. Summary Report Overview GBI Research, the leading business intelligence provider, has released its latest research, Psoriasis Therapeutics in Asia-Pacific Markets to 2021: Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth, which provides insights into psoriasis therapeutics in the Asia-Pacific (APAC) market. For the purposes of this report, APAC refers to the market in China, India, Japan, and Australia only. The report estimates the market size for 2014, along with forecasts until 2021. It also covers disease epidemiology, treatment algorithms, treatment use patterns, in-depth analysis of pipeline molecules, clinical trial failure rates, and analysis of recent deals. It is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis carried out by GBI Researchs team of industry experts. Read more details at: http://www.bigmarketresearch.com/psoriasis-therapeutics-in-asia-pacific-to-2021-advent-of-novel-biologics-and-expanding-treatment-pool-to-drive-growth-market

3. Key Benefits Key Benefits In 2014, the value of the psoriasis therapeutics market in APAC amounted to an estimated $690m, and it is forecast to grow at a Compound Annual Growth Rate (CAGR) of 8.4% between 2014 and 2021 to reach $1.2 billion. The psoriasis treatment landscape is a particularly complex one. More than 80% of patients fall into the mild-or-moderate category, for which the first line of treatment is topical drugs, phototherapy, or a combination. In the case of severe patients, non-steroidal drugs such as methotrexate, cyclosporine, and acitretin are practiced as first-line treatment; however, they come with toxicity concerns and so cannot be prescribed for long durations. Biologics such as TNF inhibitors (adalimumab, etanercept, infliximab) and ustekinumab are largely prescribed as second-line therapy when none of the aforementioned options provide the desired results. However, during the forecast period, biologics are likely gain a significant patient share due to healthcare plans in APAC and awareness regarding the effectiveness of biologics. Among the recently launched biologics, Cosentyx (secukinumab) from Novartis has shown better efficacy than Enbrel (etanercept), and is a novel molecule that targets Interluekin-17 (IL-7). Biocon India has launched Alzumab (itolizumab), which is a first-in-class novel molecule that targets CD6 protein.

4. Key Benefits Scope The report analyzes treatment use patterns, market characterization, the pipeline, and key licensing and co-development deals for psoriasis in the APAC markets of China, India, Japan, and Australia.The report includes – - A brief introduction to psoriasis, including pathophysiology, etiology, diagnosis, and treatment algorithms - In-depth analysis of currently marketed drugs, including analysis of safety, efficacy, treatment patterns, and strengths/weaknesses, along with a heat map comparing them in terms of safety and efficacy - A comprehensive review of the pipeline for psoriasis, including individual analysis of a number of late-stage pipeline drugs likely to enter the market during the forecast period; the pipeline is further analyzed on the basis of phase distribution, molecule type, program type, mechanism of action, and molecular target - Additional in-depth analysis of pipeline drug clinical trials by phase, trial size, trial duration, and program failure rate for each molecule type - Multi-scenario forecast data for the market to 2021, taking into account how it might be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across the key developed markets

5. Table of Contents: 1 Table of Contents 5 2 Introduction 9 3 Marketed Products 18 4 Psoriasis Market to 2021 – Pipeline Products 29 5 Market Forecast to 2021 44 6 Deals and Strategic Consolidations 54 7 Appendix 65

6. List of Tables: Table 1: Psoriasis Market, Global, Types of Psoriasis, 2015 9 Table 2: Psoriasis Market, Therapeutics, Global, All Pipeline Products, Discovery, 2014 65 Table 3: Psoriasis Market, Therapeutics, Global, All Pipeline Products, Preclinical Phase, 2014 67 Table 4: Psoriasis Market, Therapeutics, Global, All Pipeline Products, Preclinical Phase, 2014 70 Table 5: Psoriasis Market, Therapeutics, Global, All Pipeline Products, Preclinical Phase, 2014 71 Table 6: Psoriasis Market, Therapeutics, Global, All Pipeline Products, Preclinical Phase, 2014 74 Table 7: Psoriasis Market, Therapeutics, Global, All Pipeline Products, Preclinical Phase, 2014 78 Table 8: Psoriasis Market, Therapeutics, Global, All Pipeline Products, Preclinical Phase, 2014 79 Table 9: Psoriasis Market, Asia-Pacific, Forecast Data, 2014–2021 79 Table 10: Psoriasis Market, China, Forecast Data, 2014–2021 79

7. List of Figures: Figure 1: Psoriasis Market, Global, Composite Treatment Algorithm, 2015 14 Figure 2: Psoriasis Market, Global, Humira (adalimumab), Annual Sales ($bn), 2007–2014 22 Figure 3: Psoriasis Market, Global, Enbrel (etanercept), Annual Sales ($bn), 2007–2014 23 Figure 4: Psoriasis Market, Global, Remicade (infliximab), Annual Sales ($bn), 2007–2014 25 Figure 5: Psoriasis Market, Global, Stelara (ustekinumab), Annual Sales ($bn), 2010–2014 26 Figure 6: Psoriasis Market, Global, Comparative Safety and Efficacy of Marketed Products Heatmap (1/2), 2015 27 Figure 7: Psoriasis Market, Global, Comparative Safety and Efficacy of Marketed Products Heatmap (2/2), 2015 28 Figure 8: Psoriasis Market, Global, Pipeline by Stage of Development, Program Type and Route of Administration, 2015 30

8. Enquire about report: http://www.bigmarketresearch.com/report-enquiry/245545